{"analyses":[{"ciLowerLimit":"0.369","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.792","estimateComment":"Hazard ratio is estimated using stratified Cox regression model with treatment as the only covariate.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0013","pValueComment":"P value is from stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.541","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the small number of events","groupId":"OG000","lowerLimit":"48.0","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"24.7","upperLimit":"49.8","value":"35.4"},{"comment":"Not estimable due to the small number of events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"78"}],"units":"Participants"}],"description":"TTNT is defined as the duration from the date of randomization (Randomization Phase) or date of first dose of study treatment (Treatment-Naive Arm) to the start date of any anti-lymphoma treatment subsequent to study treatment. Post-treatment stem cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, or other cellular therapies were not considered subsequent anti-cancer treatments for participants responding to the study treatment (CR or PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg) for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG000","title":"Randomization Phase: Ibrutinb + Venetoclax"},{"description":"Participants were randomized to ibrutinib 560 mg and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG001","title":"Randomization Phase: Ibrutinib + Placebo"},{"description":"Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).","id":"OG002","title":"Treatment-naive Open-label Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized and all enrolled treatment-naïve participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)","title":"Time to Next Treatment (TTNT) (Randomization Phase and Treatment-Naive Arm)","type":"SECONDARY","unitOfMeasure":"months"}